Many skeletal diseases have common pathological phenotype of defective osteogenesis of bone marrow stromal cells (BMSCs), in which histone modifications play an important role. However, few studies have examined the dynamics of distinct histone modifications during osteogenesis. In this study, we examined the dynamics of H3K9/K14 and H4K12 acetylation; H3K4 mono-, di-and tri-methylation; H3K9 di-methylation and H3K27 tri-methylation in osteogenic genes, runtrelated transcription factor 2 (Runx2), osterix (Osx), alkaline phosphatase, bone sialoprotein and osteocalcin, during C3H10T1/2 osteogenesis. H3 and H4 acetylation and H3K4 di-methylation were elevated, and H3K9 di-methylation and H3K27 tri-methylation were reduced in osteogenic genes during C3H10T1/2 osteogenesis. C3H10T1/2 osteogenesis could be modulated by altering the patterns of H3 and H4 acetylation and H3K27 tri-methylation. In a glucocorticoid-induced osteoporosis mouse model, we observed the attenuation of osteogenic potential of osteoporotic BMSCs in parallel with H3 and H4 hypo-acetylation and H3K27 hyper-tri-methylation in Runx2 and Osx genes. When H3 and H4 acetylation was elevated, and H3K27 trimethylation was reduced, the attenuated osteogenic potential of osteoporotic BMSCs was rescued effectively. These observations provide a deeper insight into the mechanisms of osteogenic differentiation and the pathophysiology of osteoporosis and can be used to design new drugs and develop new therapeutic methods to treat skeletal diseases.
marrow stromal cell (BMSC) osteogenesis (1517). BMSCs differentiation into mature osteoblasts involves several phases, such as cellular proliferation, extracellular matrix maturation and matrix mineralization. The onset of differentiation is marked by a decrease in Twist expression and an increase in runtrelated transcription factor 2 (Runx2) and osterix (Osx) expression. Committed pre-osteoblasts have increased expression of the msh homeobox 2 (Msx2) and distal-less homeobox proteins, which interact with Runx2 and Osx to forward terminal osteogenesis. Alkaline phosphatase (ALP) is expressed during the early stages of osteogenesis, and bone sialoprotein (BSP) and osteocalcin (OC) are expressed in more mature osteoblasts during matrix maturation and mineralization (18) .
The molecular mechanisms that govern BMSCs osteogenesis are not completely understood. The specific role of histone modifications has not been examined thoroughly, although over the last decade, it has been studied in diverse cellular processes including mitosis, programmed cell death and oncogenesis. To further elucidate the essential role of histone modifications in the epigenetic regulation of osteogenesis, we used chromatin immunoprecipitation (ChIP) to examine the distribution of seven histone modifications in five key osteogenic genes-Runx2, Osx, ALP, BSP and OC-at various stages of the osteogenesis of C3H10T1/2 cells. The histone modifications examined were H3K9/K14 and H4K12 acetylation; H3K4 mono-, di-and tri-methylation; H3K9 di-methylation and H3K27 tri-methylation. The results revealed the specific and dynamic patterns of histone modifications in each osteogenic gene during osteogenesis. Osteogenic gene transcription and osteogenic differentiation could be regulated through modulating histone acetylation and H3K27 tri-methylation. Furthermore, osteoporotic BMSCs from glucocorticoid-induced osteoporosis (GIO) mice, which had the attenuated osteogenic potential, had decreased H3 and H4 acetylation and increased H3K27 tri-methylation in the Runx2 and Osx genes. Attenuation of the osteogenic potential in osteoporotic BMSCs could be rescued by enhancing histone acetylation and reducing H3K27 trimethylation.
Materials and Methods
Cell culture, osteogenic differentiation and treatment BMSCs were maintained in a-modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco by Invitrogen), 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco) and then incubated in 5% CO 2 at 37 C. C3H10T1/2 cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS, 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco). The cultures were incubated in a humidified atmosphere at 37 C and 5% CO 2 . To induce osteogenic differentiation, C3H10T1/2 cells and BMSCs were treated with BMP-2 (R&D Systems, Minneapolis, MN, USA) at final concentrations of 200 and 150 ng/ml, respectively.
C3H10T1/2 cells and BMSCs were treated with nicotinamide and trichostatin A (TSA) (Sigma, St. Louis, MO, USA) at final concentrations of 10 mM and 100 nM, respectively.
ALP staining and Alizarin Red staining
Cultured cells were rinsed with phosphate buffered saline (PBS) three times and fixed with 4% paraformaldehyde for 10 min at 4 C. The fixed cells were soaked in 0.1% naphthol AS-MX phosphate (Sigma) and 0.1% fast red violet LB salt (Sigma) in 56 mM 2-amino-2-methyl-1,3-propanediol (Sigma) for 10 min at room temperature, washed with PBS, and then observed under a digital camera.
Osteoblast maturation was examined by staining mineralized nodules with Alizarin Red. After fixation, the cells were washed with PBS and soaked in 40 mM Alizarin Red (pH 4.2) for 30 min at 37 C, then washed with PBS and imaged.
Reverse transcription-PCR and real-time PCR The total RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Single-stranded cDNA was reverse-transcribed from 1 mg of total RNA using an oligo-dT primer. Reverse transcription-polymerase chain reaction (RT-PCR) was performed with 1 ml of cDNA using the following cycling parameters: 30 cycles of 94 C for 40 s, 60 C for 40 s and 72 C for 40 s. Real-time PCR was performed on a 96-well-plate ABI Prism 7500 (Applied BioSystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (Takara Bio Inc., Otsu, Japan). Cycling conditions were as follows: 94 C for 30 s, 40 cycles of 94 C for 5 s and 60 C for 34 s. The comparative 2
ÀÁÁCt method was used to calculate the relative expression of each target gene. The following primer sequences were used for RT-PCR: SETDB1:
0 (reverse). The primer sequences used for realtime PCR were as follows: Runx2:
Western blot analysis Histone preparations were made from cells collected at various time points during osteogenesis. Equal amounts of core histones were resolved by 15% SDSPAGE, transferred onto Polyvinylidene fluoride (PVDF) membranes and probed with the following antibodies: H3K4 mono-methylation (Abcam, Cambridge, MA, USA), H3K4 di-methylation (Upstate, New York, NY, USA), H3K4 trimethylation (Upstate), H3K9/K14 acetylation (Upstate), H4K12 acetylation (Upstate), H3K9 di-methylation (Abcam), H3K27 trimethylation (Upstate), total H3 (Abcam) and total H4 (Abcam).
Chromatin immunoprecipitation
Cells were cross-linked with 1% formaldehyde for 10 min at 37 C, and crude nuclei were purified using a previously described protocol (19) . The crude nuclei were sonicated to obtain chromatin fragments $500 bp in length. The antibodies used in the ChIP assay were the same as those described earlier for western blot. Rabbit IgG (Sigma) was used as a negative control. For each ChIP assay, 25 mg of antibodies was added, and the samples were incubated overnight at 4 C. The ChIP and input DNA were quantified by real-time PCR. For all osteogenic genes, À2 and À1 kb primers targeting the regions 2 and 1 kb upstream of the transcription start site (TSS), respectively, were used. Promoter primers were designed to be within 500 bp upstream of the TSS. Primer sequences for ChIPqPCR are listed in Supplementary Table S1 .
RNAi Lentiviral vectors containing short interfering (si) RNAs against SETDB1 and Ezh2 were purchased from Genecopoeia TM (Rockville, MD, USA). Virus particles were generated as previously described (16) . Briefly, 1.31.5 Â 10 6 293 T cells were plated in a 10-cm dish, and the transfection mixture was added directly to the Y.-X. Zhang et al.
culture medium when the cells were 7080% confluent. After transfection, the samples were incubated in a CO 2 incubator at 37 C for 48 h, and the medium containing viral particles was then collected.
GIO mouse model BALB/c mice (7 months old) were caged under standard conditions. The mice were dosed once daily intraperitoneally with saline or dexamethasone phosphate (5 mg/kg; Sigma) for 3 weeks. The animals were then sacrificed with sodium pentobarbitone. The femur was removed by dissection for micro-computerized tomography analysis. BMSCs were harvested for further experiments. The treatment protocol was approved by the Ethics Committee and the Animal Research Committee, Shanghai Jiaotong University School of Medicine.
Statistical analysis
The significance of differences was calculated using Student's t-test for two-sample comparisons and ANOVA for multiple comparisons. Tukey's test was used to identify significant differences in ANOVA. Significance was analysed using data from at least three independent experiments. P-values 50.05 were defined as significant. All data are presented as the means ± SD unless otherwise specified.
Results
Expression profiles of osteogenic genes during osteogenesis of C3H10T1/2 cells C3H10T1/2 is a cell line that was established from an early mouse embryo and has the potential for osteogenesis, chondrogenesis and adipogenesis (20) ; this cell line has been used extensively as an in vitro model to examine the differentiation of mesenchymal cells into various phenotypic lineages (2123).
In this study, we treated confluent C3H10T1/2 cells with 200 ng/ml BMP2. At week 1, ALP staining analysis revealed that BMP2 induction activated ALP (Fig. 1A) . At week 3, Alizarin Red staining analysis revealed that mineralization was greater upon BMP2 induction than without BMP2 induction (Fig. 1B) . The total RNA was extracted at weeks 0, 1, 2 and 3 with and without BMP2 induction and used for quantitative RT-PCR analysis. At various time points, there was significant upregulation of the mRNA expression of osteogenic genes in response to BMP2 induction. Runx2 mRNA levels peaked at week 1 and then decreased progressively during weeks 2 and 3 ( Fig.  1C) . Osx mRNA levels increased progressively from weeks 1 to 3 (Fig. 1D) . ALP mRNA levels showed the same pattern as Runx2 (Fig. 1E) . BSP mRNA levels showed the same pattern as Osx (Fig. 1F) . OC mRNA levels were higher only 3 weeks after BMP2 induction compared with untreated cells, and there was no significant difference in the OC mRNA levels at weeks 1 and 2 with and without BMP2 induction (Fig. 1G ). These data suggested that each osteogenic gene had its specific time frame of expression during C3H10T1/2 osteogenesis.
Global levels of histone modifications during osteogenesis In this study, we aimed to investigate the patterns of histone modifications in osteogenic genes during osteogenesis. First, we examined the global levels of seven core histone modifications. Core histones were isolated from C3H10T1/2 cells at weeks 0, 1, 2 and 3 after BMP2 induction, and specific antibodies against H3K4 mono-, di-and tri-methylation, H3K9/K14 acetylation, H4K12 acetylation, H3K9 di-methylation and H3K27 tri-methylation were used to examine the levels of the respective histone modifications in western blot. Total H3 and H4 were used as loading controls. As shown in Fig. 2A , the global levels of the examined histone modifications remain unchanged during osteogenesis of C3H10T1/2 cells.
Histone loss in the regulatory regions of osteogenic genes during osteogenesis Active gene transcription is usually characterized by histone loss and incompact chromatin structure in the gene promoter (2426). Through ChIP assay, the distribution of H3 was measured in osteogenic genes. These genes were selected because of their significant roles in osteogenesis and also because they are examples of key transcriptional factor (Runx2 and Osx), early activated (ALP) and middle to late activated osteogenic genes (BSP and OC). For each gene, four regions were examined: regions 2 and 1 kb upstream of the TSS, the promoter and exon. There were no differences in H3 occupancy in the four regions for Runx2 among various time points during osteogenesis (Fig. 2B ). In the Osx gene, H3 occupancy was lost in the À2 kb (weeks 1 and 2), À1 kb (weeks 1, 2 and 3) and promoter (weeks 2 and 3) regions compared with week 0 (Fig. 2C ). In the ALP gene, H3 occupancy was lost in the À2 kb (weeks 1, 2 and 3) and À1 kb (weeks 2 and 3) regions compared with week 0 (Fig. 2D) . Loss of H3 occupancy in the BSP gene was similar to that in the ALP gene (Fig. 2E ). In the OC gene, loss in H3 occupancy only occurred in the À2 kb and promoter regions at week 3 of osteogenesis compared with week 0 (Fig. 2F) . No loss of H3 occupancy was observed in the exon region in these five genes during osteogenesis (Fig. 2BF ). IgG was used as negative control ( Supplementary Fig.  S1AE ). In contrast, when C3H10T1/2 cells were not induced to undergo osteogenic differentiation, no H3 loss was observed in these osteogenic genes ( Supplementary Fig. S2 ). Given that each osteogenic gene has its specific time frame of expression during osteogenic differentiation, these data described earlier suggested that there was a relationship between histone 3 loss and osteogenic gene expression during osteogenesis.
Patterns of H3K9/K14 and H4K12 acetylation in osteogenic genes during osteogenesis In this study, the roles of histone 3 and 4 acetylation in osteogenic genes were studied during osteogenesis of C3H10T1/2 cells. We selected H3K9/K14 and H4K12 acetylation to represent H3 and H4 acetylation, respectively. The results from ChIP assay showed that H3K9/K14 acetylation at weeks 1, 2 and 3 was significantly increased in the À2, À1 kb and promoter regions of Runx2 after BMP2 induction relative to week 0 (Fig. 3A ), but this pattern was not observed for H4K12 acetylation (Fig. 3F ). In the Osx gene, H3K9/K14 and H4K12 acetylation were significantly increased in the À1 kb region ( Fig. 3B and G ), but there was only a modest increase in H3K9/K14 acetylation in the promoter region (Fig. 3B) . Increased H3K9/K14 acetylation was observed in the À2 and À1 kb regions of ALP (Fig. 3C ). In the BSP gene, there was increased H3K9/K14 and H4K12 acetylation in some regions relative to week 0 ( Fig. 3D and  I ). In the OC gene, increased H3K9/K14 and H4K12 acetylation were observed in some regions only at the terminal stage of osteogenesis ( Fig. 3E and J) . Histone acetylation is a marker of active chromatin region, which was confirmed in this report by observing that both H3 and H4 acetylation correlate positively with osteogenic gene expression during osteogenesis (Figs 1  and 3) .
Patterns of H3K4, K9 and K27 methylation in osteogenic genes during osteogenesis Histone H3K4 can be mono-, di-or tri-methylated, and each form of methylation has specific biological functions. To examine the roles of H3K4 methylation in osteogenesis of C3H10T1/2 cells, we examined the distribution of all three types of methylation in five osteogenic genes using ChIP assays. In four regions of all five genes, we observed no difference in H3K4 mono-and tri-methylation among various time points during osteogenesis (Supplementary Figs S3 and S5). We observed increased H3K4 di-methylation in the À1 kb and promoter regions of Runx2 and the À2, À1 kb and promoter regions of Osx during osteogenesis ( Fig. 4A and B) . In the ALP, BSP and OC genes, there was no obvious difference in H3K4 dimethylation during osteogenesis ( Supplementary Fig.  S4 ).
Di-methylated H3K9 and tri-methylated H3K27 are repressive marks (26, 27) . In this study, we observed that H3K9 di-methylation was decreased significantly in some regions of Runx2, Osx and OC. H3K9 di-methylation was decreased in the À2, À1 kb and promoter regions of Runx2 (Fig. 4C) and Osx (Fig. 4D ) and the À1 kb and promoter regions of OC (Fig. 4E ) during osteogenesis. Furthermore, no differences were observed in H3K9 di-methylation in the four regions of ALP and BSP during osteogenesis ( Supplementary Fig. S6 ). In contrast, H3K27 tri-methylation was decreased in the À1 kb and promoter regions of Runx2 (Fig. 4F ) and in the À2, À1 kb and promoter regions of Osx (Fig. 4G ) during osteogenesis. No differences were observed in H3K27 tri-methylation in the four regions of ALP, BSP and OC during osteogenesis ( Supplementary Fig. S7 ). These data described earlier suggested that H3K9 di-methylation and H3K27 trimethylation had the negative relationship with osteogenic gene activation during osteogenesis.
Modulation of C3H10T1/2 osteogenesis by altering H3K9/K14 and H4K12 acetylation in osteogenic genes We next examined whether the distribution of various histone modifications in the Runx2, Osx, ALP, BSP and OC genes could be used to elucidate the specific epigenetic mechanism controlling the expression of these osteogenic genes and the osteogenesis of C3H10T1/2 cells. We observed that histone acetylation in these five osteogenic genes positively correlate with gene expression during osteogenesis (Figs 1 and 3) . To directly test whether increased histone acetylation affects expression of these genes, we inhibited HDACs by treating C3H10T1/2 cells with nicotinamide and TSA. ChIP analysis revealed that treatment with these drugs led to a general increase in both H3K9/ 14 ( Fig. 5A) and H4K12 (Fig. 5B ) acetylation in the promoters of these osteogenic genes regardless of with and without BMP2 induction. In parallel, real-time PCR analysis revealed elevated mRNA expression of these five genes (Fig. 5CG) . Furthermore, we treated C3H10T1/2 cells with BMP2 together with nicotinamide and TSA. The total RNA was extracted and used for real-time PCR analysis. There was a significant increase in Runx2, Osx, ALP, BSP and OC mRNA expression in response to BMP2 + nicotinamide + TSA treatment compared with BMP2 treatment alone (Fig. 5CG) suggesting that BMP2-induced C3H10T1/2 osteogenesis was enhanced by the nicotinamide-and TSA-induced increase of H3 and H4 acetylation. These observations were consistent with the results of ALP staining (Fig.  5H) and Alizarin Red staining (Fig. 5I) analysis performed at week 1 and 3 after induction; ALP activity and mineralization were more extensive in response to BMP2 + nicotinamide + TSA treatment compared with BMP2 treatment alone.
Modulation of C3H10T1/2 osteogenesis by altering the patterns of H3K27 tri-methylation in osteogenic genes In the Runx2, Osx and OC genes, we observed that both H3K9 and K27 methylation negatively correlated with gene expression during osteogenesis (Figs 1 and  4) . To directly test whether H3K9 and K27 methylation controlled osteogenic gene expression and C3H10T1/2 osteogenesis, we decreased H3K9 and H3K27 methylation in these genes. As the data from RT-PCR shown, siRNA was employed to silence the expression of Ezh2, a H3K27 methyltransferase that is responsible for adding methyl groups to H3K27 (26) Fig. 4 H3K4 di-methylation, H3K9 di-methylation and H3K27 tri-methylation patterns in osteogenic genes during C3H10T1/2 osteogenesis. Levels of H3K4 di-methylation, H3K9 di-methylation and H3K27 tri-methylation in the À2, À1 kb, promoter and exon regions of Runx2 (A, C and F), Osx (B, D and G) and OC (E) during osteogenesis of C3H10T1/2 cells were examined by ChIP analyses. The results were normalized to the percentage of H3K4 and H3K9 di-methylation and H3K27 tri-methylation in the input control. The data are presented as the means ± SD. *Indicates P50.05 relative to week 0.
Y.-X. Zhang et al. (Fig. 6A) . ChIP analysis revealed that treatment with the Ezh2 siRNA led to a general decrease in H3K27 tri-methylation in the Runx2, Osx, ALP, BSP and OC promoters regardless of with and without BMP2 induction (Fig. 6B) . In parallel, real-time PCR analysis revealed elevated Runx2, Osx, ALP, BSP and OC mRNA expression (Fig. 6CG) . Furthermore, BMP2 was used to induce C3H10T1/2 cells with and without Ezh2 knockdown. The total RNA was extracted and used for real-time PCR analysis. There was a significant increase in Runx2, Osx, ALP, BSP and OC mRNA expression upon BMP2 induction and Ezh2 knockdown compared with BMP2 induction alone (Fig. 6CG) suggesting that BMP2-induced C3H10T1/2 osteogenesis was enhanced by decreased H3K27 tri-methylation. These data were consistent Fig. 6 Modulation of C3H10T1/2 osteogenesis by altering the patterns of H3K27 tri-methylation in osteogenic genes. The results from RT-PCR showed that Ezh2 expression in C3H10T1/2 cells was downregulated in response to siRNA against Ezh2 (A). Samples were collected to examine H3K27 tri-methylation levels in the Runx2 and Osx promoters with and without BMP2 induction using ChIP (B). The results were normalized to the percentage of H3K27 tri-methylation in the input control. The total RNA was extracted and used for real-time PCR analysis with primers for Runx2 (C), Osx (D), ALP (E), BSP (F) and OC (G). b-Actin was used as an internal control, and the results were expressed as fold changes relative to the scrambled-siRNA-treated BMP2 (À) culture. ALP staining (H) and Alizarin Red staining (I) were performed at weeks 1 and 3, respectively. The data are presented as the means ± SD. *Indicates P50.05 relative to the scrambled-siRNA-treated control. Fig. 5 Modulation of C3H10T1/2 osteogenesis by altering H3K9/K14 and H4K12 acetylation in osteogenic genes. C3H10T1/2 cells were treated with DMSO (vehicle) or nicotinamide and TSA, and samples were collected to examine H3K9/K14 (A) and H4K12 (B) acetylation levels in the Runx2, Osx, ALP, BSP and OC promoters with and without BMP2 induction using ChIP. The results were normalized to the percentage of H3K9/K14 and H4K12 acetylation in the input control. The total RNA was extracted and used for real-time PCR analysis with primers for Runx2 (C), Osx (D), ALP (E), BSP (F) and OC (G). b-Actin was used as an internal control, and the results were expressed as fold changes relative to vehicle-treated BMP2 (À) culture. At week 1 and 3, ALP staining (H) and Alizarin Red staining (I) were performed, respectively. The data are presented as the means ± SD. *Indicates P50.05 relative to vehicle treatment.
Histone modifications in osteogenic differentiation
with results of ALP staining (Fig. 6H) and Alizarin Red staining (Fig. 6I ) assays performed at weeks 1 and 3, respectively, after induction; ALP activity and mineralization were more extensive upon Ezh2 knockdown compared with treatment with BMP2 alone.
We also used siRNA to silence the expression of SETDB1, H3K9 methyltransferase (28) (Supplementary Fig. S8A ). ChIP analysis revealed that treatment with the SETDB1 siRNA led to a general decrease in H3K9 di-methylation in the Runx2, Osx and OC promoters (Supplementary Fig. S8B ). However, no differences were observed in Runx2, Osx, ALP and OC mRNA expression in C3H10T1/2 cell cultures between with and without SETDB1 silence regardless of BMP2 induction; BSP expression showed a minor increase in response to SETDB1 siRNA when without BMP2 induction (Supplementary Fig.  S8CG ).
The attenuated osteogenesis potential of osteoporotic BMSCs is rescued by modulating the patterns of histone acetylation and H3K27 tri-methylation As described earlier, we characterized the distribution of various histone modifications in the Runx2, Osx, ALP, BSP and OC genes and confirmed that C3H10T1/2 osteogenesis was enhanced by increasing H3 and H4 acetylation and decreasing H3K27 trimethylation. We then examined whether these histone modifications are involved in skeletal diseases and more importantly, whether these histone modifications can be used to modulate BMSCs osteogenesis in skeletal diseases. We previously developed a mouse model of GIO (17) . We isolated normal and osteoporotic BMSCs from bone marrow of saline-treated and GIO mice. Notably, there was no difference in Runx2, Osx, ALP, BSP and OC mRNA expression in BMSCs from both types of mice ( Supplementary  Fig. S9 ). However, upon in vitro BMP2-induced osteogenic differentiation, osteoporotic BMSCs showed weaker osteogenic potential compared with normal BMSCs (Fig. 7A and B) . We then used ChIP assays to examine the acetylation of H3 and H4 and H3K27 tri-methylation in the four regions described earlier in the Runx2 and Osx genes of BMSCs. Compared with normal BMSCs, H3K9/K14 acetylation was significantly decreased in the À2, À1 kb and promoter regions of Runx2 and the À1 kb, promoter and exon regions of Osx in osteoporotic BMSCs (Fig. 7C and  D) . Compared with normal BMSCs, H4K12 acetylation was significantly decreased in the À1 kb and promoter regions of Runx2 and Osx in osteoporotic BMSCs (Fig. 7C and D) . In contrast, compared with normal BMSCs, H3K27 tri-methylation was increased in the À2, À1 kb and promoter regions of Runx2 and the À1 kb and promoter regions of Osx in osteoporotic BMSCs (Fig. 7E) . It should be noted that upon osteogenic induction, H3K9/K14 and H4K12 hypoacetylation and H3K27 hyper-tri-methylation in the regulatory regions of Runx2 and Osx were also observed in osteoporotic BMSCs compared with normal BMSCs (Supplementary Fig. S10 ).
We then tested whether the attenuated osteogenic potential of osteoporotic BMSCs could be rescued by modulating histone acetylation and H3K27 trimethylation. Nicotinamide and TSA were used to inhibit HDACs in osteoporotic BMSCs. BMP2 was used to induce osteogenesis in osteoporotic BMSCs with and without treatment with nicotinamide and TSA. As a positive control, normal BMSCs were induced osteogenesis by BMP2. The total RNA was extracted and used for real-time PCR analysis. There was a significant increase in Runx2, Osx, ALP, BSP and OC mRNA expression in osteoporotic BMSCs in response to BMP2 + nicotinamide + TSA treatment compared with BMP2 treatment alone (Fig. 7F) , although the levels of Runx2, Osx, BSP and OC were a little lower than that in normal BMSCs. These data were supported by the results from ALP staining and Alizarin red staining assays (Fig. 7G) .
We also used siRNA to silence Ezh2 expression to decrease H3K27 tri-methylation. Real-time PCR analysis revealed that there was a significant increase in Runx2, Osx, ALP and OC mRNA expression in osteoporotic BMSCs in response to Ezh2 knockdown compared with the scrambled siRNA control (Fig. 7H) , although the levels of Runx2, ALP and OC were a little lower than that in normal BMSCs. These results were consistent with ALP and Alizarin Red staining assays performed at weeks 1 and 3, respectively, after induction; ALP activity and mineralization of osteoporotic BMSCs were more extensive in response to Ezh2 knockdown relative to the control (Fig. 7I) . These data suggested that the attenuated osteogenesis potential of osteoporotic BMSCs could be rescued effectively by modulating the patterns of histone acetylation and H3K27 tri-methylation.
Discussion
Osteogenic differentiation is a complicated process requiring a cascade of biological events and precise co-operation of various osteogenic factors, in which various histone-modifying enzymes are included suggesting that epigenetic modifications exert important biological functions in osteogenesis. In this report, we observed that every osteogenic gene had its own specific histone modification pattern and distinct histone modifications are highly dynamic in specific osteogenic genes during osteogenesis. Furthermore, modulating these histone modifications affects expression of the osteogenic genes and osteogenesis of C3H10T1/2 cells.
Genome-wide analyses of gene transcription have shown that many genes are differentially expressed during BMSC differentiation. For example, Burton et al. (29) investigated 12,488 genes totally using microarrays and found out that 1,686 genes showed a >2-fold expression change during adipogenesis with 859 transcripts upregulation and 827 transcripts downregulation. In a later study, Song et al. compared the global gene expression profiles of undifferentiated and differentiated cells in three lineages (osteoblasts, chondrocytes and adipocytes). They identified a number of 'stemness' and 'differentiation' genes that might play an essential role in maintaining adult stem cell multipotency and to drive lineage-specific commitment (30) . As histone modifications are tightly involved to gene transcription, and gene transcription is responsible for the stability of the whole transcriptome of BMSCs, we speculated that it is difficult for the global levels of histone modifications to change significantly unless these modifications are accumulated at groups of upregulated or downregulated genes by chance. Indeed, the results from western blot showed that the bulk levels of all seven examined histone modifications remain stable during osteogenesis of C3H10T1/2 cells (Fig. 2A) . Furthermore, these observations ruled out the possibility that the genespecific changes in histone modification states are due to their fluctuation at the global level.
Upon transcription activation, the nucleosome generally undergoes three progressive steps of structural changes, that is, histone modifications, unfolding and histone loss (24, 25) . Histone loss represents significant transcription activity of gene promoter. In this study, histone loss in the regulatory regions of five osteogenic genes was investigated during C3H10T1/2 osteogenesis using ChIP assay. Of those five osteogenic genes, ALP Fig. 7 The attenuated osteogenic potential of osteoporotic BMSCs can be rescued by altering the patterns of histone acetylation and H3K27 trimethylation. BMSCs were isolated from normal and GIO mice. ALP staining and Alizarin Red staining were performed at weeks 1 and 3 after BMP2 induction, respectively (A). The total RNA was extracted and used for real-time PCR analysis with primers for Runx2, Osx, ALP, BSP and OC (B). The results were expressed as fold changes relative to normal BMSCs culture without BMP2 induction. Levels of histone H3K9/K14 (C) and H4K12 (D) acetylation and H3K27 tri-methylation (E) in Runx2 and Osx of normal and osteoporotic BMSCs were examined by ChIP analyses. The results were normalized to the percentage of H3K9/K14 and H4K12 acetylation and H3K27 tri-methylation in the input control. *Indicates P50.05 and **indicates P50.01 for GIO mice versus normal mice. Osteoporotic BMSCs were treated with nicotinamide and TSA (N + T) to inhibit HDAC and with anti-Ezh2 siRNA to downregulate Ezh2 expression; the total RNA was then extracted and used for real-time PCR using primers for Runx2, Osx, ALP, BSP and OC (F and H). The results were expressed as fold changes relative to osteoporotic BMSCs medium culture. b-Actin was used as an internal control for real-time PCR. The data were presented as the means ± SD. *Indicates P50.05 and **indicates P50.01. ALP staining and Alizarin Red staining were performed at weeks 1 and 3 after BMP2 induction, respectively (G and I).
and BSP, which have the most significant upregulation of transcription during osteogenesis had the most significant histone loss. Furthermore, the time frame of histone loss in osteogenic genes was generally consistent with the time frame of osteogenic gene transcription during osteogenesis. Our data suggested the close relationship between histone loss and gene transcription.
Runx2 is essential for osteoblast differentiation and chondrocyte maturation. In this study, we observed that Runx2 mRNA levels showed a biphasic response to BMP2 induction during C3H10T1/2 osteogenesis (Fig. 1C) . To elucidate the epigenetic mechanisms underlying expression of the Runx2 gene during C3H10T1/2 osteogenesis, we examined the distribution of seven histone modifications in the À2, À1 kb, promoter and exon regions of Runx2. Consistent with the gene expression profiles, Runx2 had higher levels of active chromatin marks, such as H3 and H4 acetylation, and H3K4 di-methylation in osteogenic C3H10T1/2 cells compared with uncommitted C3H10T1/2 cells. Further functional studies revealed that H3 and H4 acetylation were involved in Runx2 expression during C3H10T1/2 osteogenesis. These results are consistent with previous studies showing that acetylation of histone H3K9 in the Runx2 and Osx promoter regions is enhanced during osteogenic differentiation of BMSCs and adipose-derived stem cells (31, 32) . HDACs 18 play inhibitory roles in osteoblast differentiation by regulating histone acetylation or interacting with Runx2 (31, 3335). HDAC inhibitors (HDIs), such as valproic acid and sodium butyrate, are often used to promote osteoblast differentiation and maturation (3537). However, considering the functions of HDACs and the pleiotropic effects of pan-HDIs (38) , clinical use of HDIs should be approached with caution.
Unlike H3K4 methylation, H3K9 and K27 methylation are repressive chromatin marks. K9 trimethylation recruits heterochromatin-associated protein-1 to establish heterochromatic regions (4), whereas K27 tri-methylation is involved in PcGmediated gene silencing (39) . Kim et al. (40) observed that bone development during the neonatal stage was facilitated by overexpression of plant homeodomain finger protein 2, which is a histone demethylase that reverses di-methylation of histone H3K9, suggesting that H3K9 di-methylation plays a negative role in bone development. However, inconsistent results were observed in another study. Lawson et al. analysed the bone phenotype in mice harbouring a mesenchymal-specific deletion of the SET domain of SETDB1. In these mice, the SETDB1 KO severely impaired osteoblast differentiation and was associated with deregulation of Runx2 and Indian hedgehog (13) . Notably, we observed lower levels of H3K9 dimethylation in Runx2, Osx and OC in osteogenic C3H10T1/2 cells compared with uncommitted C3H10T1/2 cells. However, when SETDB1 expression was silenced by siRNA, no change was observed in C3H10T1/2 osteogenesis. This apparent discrepancy likely results from the complex role of H3K9 methylation in osteoblast differentiation. Therefore, further studies are required to elucidate the role of this histone modification in osteogenesis.
H3K27 is another repressive chromatin mark; lower levels of H3K27 tri-methylation were observed in osteogenic C3H10T1/2 cells compared with undifferentiated C3H10T1/2. Silencing the expression of Ezh2 using siRNA caused decreased tri-methylation of H3K27 in Runx2 and Osx and increased C3H10T1/2 osteogenesis suggesting that H3K27 tri-methylation plays a negative role in C3H10T1/2 osteogenesis. These results are consistent with previous studies. Yang et al. (41) observed that silencing of KDM1 lysine (K)-specific demethylase 6B expression increased H3K27 tri-methylation in the Runx2 and Osx promoter regions and suppressed osteoblast differentiation and bone formation. Expression of the ubiquitously transcribed tetratricopeptide repeat X chromosome (Utx) protein, another H3K27-me3 demethylase, also increased during osteoblast differentiation; knockdown of Utx expression decreased expression of bone-related genes including Runx2 and Osx (41) . Together with these studies, our results are consistent with the hypothesis that H3K27 trimethylation is an important epigenetic regulator of osteoblast differentiation.
Of various osteogenic genes, OC promoter containing binding sites for many osteogenic factors is most thoroughly investigated. Increased H3 and H4 acetylation and decreased DNA methylation provide accessibility of the OC promoter to transcription factors (4244). The changes of chromatin structure in the OC promoter, which support gene transcription, were resulted from vitamin D-dependent activation (45) . During vitamin D-induced activation, Runx2 together with C/EBP family members and several chromatinremodelling factors forms a protein complex to activate OC transcription (46, 47) . Furthermore, the MINT protein provides structural support for osteoblast nuclear matrix and exerts important functions in Runx2-and Msx2-dependent transcription with chromatin remodelling (48) . In this study, we examined the patterns of seven histone modifications in four regions of the OC gene during C3H10T1/2 osteogenesis. Higher levels of H3 and H4 acetylation and lower levels of H3K9 di-methylation were observed in osteogenic C3H10T1/2 cells compared with un-committed C3H10T1/2 cells. Functional studies revealed that H3 and H4 acetylation contributed to the expression of OC during C3H10T1/2 osteogenesis.
As a skeletal disease, osteoporosis is characterized by bone mass decrease and microarchitectural disorder of bone tissue, which is followed by a consequent increase in bone fragility and fracture susceptibility. Osteoporotic fractures have significant economic and health effects. There is increasing evidence that epigenetic mechanisms are central to the origin of osteoporosis. However, most studies have focused on DNA methylation, and few studies have examined the role of histone modifications in osteoporosis. In this study, we examined the patterns of seven histone modifications in four regions in the Runx2 and Osx genes in osteoporotic BMSCs. We used the GIO mouse model described previously and observed attenuation of osteogenic potential in osteoporotic BMSCs. Furthermore, we observed decreased H3 and H4 acetylation and increased H3K27 tri-methylation in Runx2 and Osx.
In this study, we attempted to rescue osteoporotic BMSCs potential for osteogenic differentiation by altering histone modifications using two methods: gene engineering and treatment with exogenous inhibitors. siRNA against Ezh2 caused Ezh2 downregulation, nicotinamide and TSA treatment caused HDAC1 inhibition. In response to these treatments, osteoporotic BMSCs osteogenic differentiation was effectively rescued. Investigations into osteoporosis epigenetics may provide not only deeper insight into osteoporosis pathophysiology but also reveal specific genes as new targets for epigenetics-based osteoporosis therapy. Some agents for epigenetic regulation are already employed to treat tumours (49, 50) , and perhaps these agents can be used in osteoporosis; however, their widespread effects are some of most significant detractions limiting their potential utility. Agents that can specifically modulate the epigenetic modifications of certain genes in a given pathway would be of much greater use. Alternatively, some drugs that are already used in osteoporosis treatment have been reported to induce epigenetic modifications by regulating HDAC activity in osteoblasts (51) . Resveratrol, a polyphenolic phytoestrogen, was shown to have anticatabolic properties in bone tissue, presumably through the modulation of HDAC sirtuin 1 activity (52).
In summary, using a model of BMP2-induced C3H10T1/2 osteogenesis, we examined the patterns of seven histone modifications in the osteogenic genes Runx2, Osx, ALP, BSP and OC. H3 and H4 acetylation and H3K4 di-methylation were elevated, and H3K9 di-methylation and H3K27 tri-methylation were reduced during C3H10T1/2 osteogenesis. The patterns of these histone modifications were closely associated with the specific expression patterns of osteogenic genes during osteogenesis of C3H10T1/2 cells. By altering the patterns of histone acetylation and H3K27 tri-methylation, C3H10T1/2 osteogenesis could be modulated. We also observed H3 and H4 hypo-acetylation and H3K27 hyper-tri-methylation in the Runx2 and Osx genes in osteoporotic BMSCs. When we elevated H3 and H4 acetylation and reduced H3K27 tri-methylation, the attenuated osteogenic potential of osteoporotic BMSCs was rescued.
